Prostaglandin E1
| Code | Size | Price |
|---|
| CDX-P0450-M005 | 5 mg | £89.00 |
Quantity:
| CDX-P0450-M010 | 10 mg | £126.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
BLUE ICE
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
(11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; Alprostadil; PGE1
Appearance:
White to off-white powder.
CAS:
745-65-3
Class:
6.1
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS06,GHS08
Handling Advice:
Protect from light and moisture.
Hazards:
H301-H361
InChi:
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
InChiKey:
GMVPRGQOIOIIMI-DWKJAMRDSA-N
Long Description:
Chemical. CAS: 745-65-3. Formula: C20H34O5. MW: 354.49. Prostaglandin E1 (PGE1) is an endogenous prostaglandin used as a medication. Its synthetic form, alprostadil, is a vasodilator and smooth muscle relaxant used for several different medical purposes. PGE1 is the theoretical cyclooxygenase metabolite of dihomo-gamma-linolenic acid (DGLA), but it is virtually undetectable in the plasma of normal humans or other animals. Its pharmacology includes vasodilation, hypotension and anti-platelet activities. The IC50 of PGE1 for the inhibition of ADP-induced human platelet aggregation is 40 nM. The vasorelaxant and anti-hypertensive effects of PGE1 are used to treat male erectile dysfunction and to provide emergency vasodilation of the patent ductus arteriosus in infants whose cardiac anomalies require pulmonary shunting for survival.
MDL:
MFCD00077860
Molecular Formula:
C20H34O5
Molecular Weight:
354.49
Package Type:
Vial
PG:
III
Precautions:
P281-P301 + P310
Product Description:
Prostaglandin E1 (PGE1) is an endogenous prostaglandin used as a medication. Its synthetic form, alprostadil, is a vasodilator and smooth muscle relaxant used for several different medical purposes. PGE1 is the theoretical cyclooxygenase metabolite of dihomo-gamma-linolenic acid (DGLA), but it is virtually undetectable in the plasma of normal humans or other animals. Its pharmacology includes vasodilation, hypotension and anti-platelet activities. The IC50 of PGE1 for the inhibition of ADP-induced human platelet aggregation is 40 nM. The vasorelaxant and anti-hypertensive effects of PGE1 are used to treat male erectile dysfunction and to provide emergency vasodilation of the patent ductus arteriosus in infants whose cardiac anomalies require pulmonary shunting for survival.
Purity:
>98% (HPLC)
Signal word:
Danger
SMILES:
O[C@@H]([C@H](/C=C/[C@@H](O)CCCCC)[C@H]1CCCCCCC(O)=O)CC1=O
Solubility Chemicals:
Soluble in DMSO (30mg/ml), DMF (50mg/ml) or ethanol (30mg/ml).
Transportation:
Excepted Quantity
UN Nummer:
2811
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
(1) F. Okada, et al.; Prostaglandins 7, 99 (1974) | (2) P.M. Olley & F. Coceani; Ann. Rev. Med. 32, 375 (1981) | (3) S.J. Kirtland; Prostaglandins Leukot. Essent. Fatty Acids 32, 165 (1988) (Review) | (4) G. Kobzar, et al.; Proceed. Est. Acad. Sci. Chem. 40, 179 (1991) | (5) H. Padma-Nathan, et al.; New Engl. J. Med. 336, 1 (1997) | (6) W. Cawello, et al.; J. Urol. 158, 1403 (1997)